David Mott, Ten Percent Owner at Oruka Therapeutics, holds 1.43M shares in Ardelyx (Ticker: ARDX), holds 50.47K shares in Novavax (Ticker: NVAX), holds 598.29K shares in Mersana Therapeutics (Ticker: MRSN). Most recently, David Mott Bought ― shares of Ardelyx on Nov 14, 2024 for an estimated value of 995.15K.
David Mott latest transaction was an Informative Buy of $995.15K.
What was David Mott's most profitable transaction?
David Mott’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
What is David Mott's role in Oruka Therapeutics?
David Mott's role in Oruka Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.